-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 15th, Yangzijiang submitted a clinical application for a new drug for Qingchang Wenzhong Tablets, which is the first class 1 new drug declared by Yangzijiang this year for proprietary Chinese medicines
.
The company's clinical application for Sanfengtongqiao dripping pills for category 2.
3 new drugs submitted in April this year has been approved, and the indication is seasonal allergic rhinitis
Figure 1: New drugs declared by Yangtze River since 2021
Source: CDE official website
Figure 2: Clinical progress of new drugs
Source: China Drug Clinical Trial Publicity Library of Meinenet
Since the beginning of this year, Yangtze River has applied for clinical application of 3 new drugs: the indication is analgesic chemical medicine Class 1 new drug YR-1702 injection and the indication is seasonal allergic rhinitis Chinese medicine Class 2.
3 new drug Sanfeng Tongqiao dripping pills have been approved.
Approval of clinical trials, of which YR-1702 injection is currently undergoing phase I clinical trials
.
Table 1: The generic status of Yangtze River's chemical drugs declared and marketed from 2021 to now
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
Compared with proprietary Chinese medicines, Yangtze River has worked more deeply in the field of chemical medicines.
Since 2021, it has submitted 30 applications for the imitation of chemical medicines, including brivaracetam injection, eslicarbazepine acetate tablets, and diquafoso sodium drops Eye drops, gadobutrol injection, lacosamide syrup, oseltamivir phosphate dry syrup, peramivir injection, regorafenib tablets and ticagrelor dispersible tablets are expected to hit the country's first imitation
.
In addition, it has also submitted generic clinical applications for obeticholic acid tablets, ranolazine sustained-release tablets, pregabalin sustained-release tablets, etomidate emulsion injection, drafloxacin for injection, and carfilzomib for injection.
Batch
Source: CDE official website, Minet database
The review data statistics are as of October 18, if there are any errors or omissions, please correct me
